Today: 7 February 2026
Subscribe
Browse Category

Healthcare News 4 February 2026 - 6 February 2026

Centene stock slides as 2026 profit view beats estimates but revenue forecast falls short

Centene stock slides as 2026 profit view beats estimates but revenue forecast falls short

Centene shares fell 5.7% to $37.64 after the company forecast 2026 adjusted profit above $3 per share but projected revenue below Wall Street estimates. Molina Healthcare dropped about 28%, weighing on the sector. Centene reported a fourth-quarter adjusted loss of $1.19 per share and a health benefits ratio of 94.3%. The company set its next earnings update for April 28.
6 February 2026
·····
McKesson stock falls today after 16% earnings surge as traders reassess guidance and spinoff clock (MCK)

McKesson stock falls today after 16% earnings surge as traders reassess guidance and spinoff clock (MCK)

McKesson shares fell 2.1% to $937.31 Friday, retreating after a 16.5% surge on an upgraded 2026 profit forecast and plans to spin off its medical-surgical division. Quarterly revenue rose 11% to $106.2 billion, with adjusted EPS up 16% to $9.34. The company filed an automatic shelf registration for future securities sales. TD Cowen raised its price target to $1,012, citing strong oncology and prescription-tech results.
6 February 2026
···
UnitedHealth (UNH) stock rebounds nearly 2% as sector digests cost shock, Mizuho trims target

UnitedHealth (UNH) stock rebounds nearly 2% as sector digests cost shock, Mizuho trims target

UnitedHealth shares rose 1.9% to $273.79 Friday, rebounding after Molina Healthcare’s weak 2026 profit outlook sent sector stocks tumbling Thursday. Mizuho cut its price target for UnitedHealth to $350 but kept an Outperform rating. Investors await the April 6 CMS decision on 2027 Medicare Advantage rates. Molina shares plunged nearly 28%, while Centene fell 5.5% and Cigna gained about 3%.
6 February 2026
·····
Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook

Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook

Coloplast A/S shares fell 7.82% to 495.35 crowns in Copenhagen after the company slashed its Kerecis growth forecast to 10% due to new U.S. Medicare reimbursement rules. Group revenue for the quarter was flat at 7,043 million crowns, with EBIT before special items down 3% to 1,850 million. Coloplast will phase out Kerecis Shield in Medicare outpatient care and shift focus to its MariGen range.
6 February 2026
···
Molina Healthcare stock sinks premarket after 2026 outlook miss, Medicare exit plan

Molina Healthcare stock sinks premarket after 2026 outlook miss, Medicare exit plan

Molina Healthcare shares fell 28.8% to $125.91 in premarket trading after the company forecast 2026 adjusted earnings of at least $5.00 per share, far below analysts’ $13.76 estimate. Molina will exit its Medicare Advantage Part D business by 2027 and reported a fourth-quarter adjusted loss of $2.75 per share. The company projects a 92.6% medical care ratio for 2026.
6 February 2026
···
Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific shares rose 2.8% to $77.64 in Thursday’s after-hours trading, rebounding after a record 17% plunge Wednesday on weak Q4 electrophysiology and Watchman sales. Citi and Wells Fargo lowered price targets but kept positive ratings. Fourth-quarter net sales reached $5.29 billion, with adjusted EPS of $0.80. The company expects 2026 adjusted EPS of $3.43–$3.49.
6 February 2026
·····
McKesson stock price jumps about 16% after profit forecast raise; MCK rallies in New York trade

McKesson stock price jumps about 16% after profit forecast raise; MCK rallies in New York trade

McKesson shares soared 16% to $953.43 after the company raised its 2026 profit outlook and beat quarterly earnings estimates. Fiscal Q3 adjusted EPS reached $9.34, topping forecasts, with revenue at $106.16 billion. U.S. pharmaceutical sales rose 9%. The company confirmed plans to spin off its medical-surgical unit by late 2027.
5 February 2026
····
UnitedHealth stock drops nearly 3% midday as Medicare Advantage rates loom — what to watch next

UnitedHealth stock drops nearly 3% midday as Medicare Advantage rates loom — what to watch next

UnitedHealth Group shares fell 2.8% to $268.23 Thursday, underperforming managed-care peers after CMS proposed a 0.09% net payment increase for Medicare Advantage in 2027 and stricter risk adjustment rules. The company expects its Medicare Advantage membership to drop by up to 1.2 million next year, according to a regulatory filing.
5 February 2026
····
Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

The FDA issued an early alert on Abiomed Impella RP heart pumps, citing a pressure sensor defect linked to 22 serious injuries but no deaths. Johnson & Johnson shares rose 0.6% to $234.47, holding steady after hours. Traders await further FDA updates and MedTech data at the AF Symposium on Feb. 6. The S&P 500 fell 0.51% while the Dow gained 0.53%.
5 February 2026
·····
UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth shares fell nearly 3% to $275.92 in after-hours trading Wednesday after the FTC announced a 10-year insulin pricing settlement with Cigna’s Express Scripts, increasing scrutiny on OptumRx and CVS Caremark. Investors are watching for an FTC oral argument Feb. 5 and a House hearing on drug prices Feb. 11. CVS and Cigna shares also declined. UnitedHealth did not comment.
5 February 2026
·······
DaVita stock price pops again as 2026 outlook fuels fresh Wall Street targets

DaVita stock price pops again as 2026 outlook fuels fresh Wall Street targets

DaVita shares rose 6.5% to close near $143.45 Wednesday after the company forecast 2026 adjusted EPS of $13.60–$15.00, above consensus. The stock surged 16% in after-hours trading Monday. Barclays and UBS raised their price targets, citing strong guidance and ongoing buybacks. DaVita reported Q4 revenue of $3.62 billion and said it repurchased 12.7 million shares in 2025.
4 February 2026
·····
Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus

Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus

Amgen shares jumped 8.5% to $367.52 in afternoon trading Tuesday, outpacing a broader market decline. The company reported Q4 revenue up 9% to $9.9 billion and projected 2026 sales as high as $38.4 billion. Investors focused on late-stage trials for obesity drug MariTide. The FDA has requested withdrawal of Tavneos, but Amgen is refusing.
4 February 2026
·····
1 2 3 … 13

Stock Market Today

SGX share price dips at week’s end after record profit; what investors watch next

SGX share price dips at week’s end after record profit; what investors watch next

7 February 2026
Singapore Exchange shares closed 0.4% lower at S$17.57 on Friday, despite reporting record half-year results and a higher dividend earlier in the week. Broker targets diverged after the update, with Maybank and DBS raising targets while Citi stayed bearish. Investors are watching for signs of momentum from derivatives and equity-market reforms as the next session opens Monday.
South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Go toTop